AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study

INTRODUCTION: Persons with haemophilia A (PwHA) commonly experience regular bleeding into joints, which may result in joint damage and complications such as degenerative arthritis. Emicizumab has previously demonstrated efficacy in reducing the occurrence of joint bleeds and target joints, along wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Shima, Midori, Takedani, Hideyuki, Kitsukawa, Kaoru, Taki, Masashi, Ishiguro, Akira, Nagao, Azusa, Yamaguchi-Suita, Haruko, Kyogoku, Yui, Yoshida, Seitaro, Nogami, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196178/
https://www.ncbi.nlm.nih.gov/pubmed/35697445
http://dx.doi.org/10.1136/bmjopen-2021-059667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196178/
https://www.ncbi.nlm.nih.gov/pubmed/35697445
http://dx.doi.org/10.1136/bmjopen-2021-059667

Ejemplares similares